ARIA News 5.57 07/16/2014 04:34:47 Ariad Pharmaceuticals (AR

New Post Public Reply Private Reply Replies (0) Message Board

Jul 16, 2014 at 5:34 AM

Ariad Pharmaceuticals (ARIA) 5.57 $ARIA

Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.

ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock

Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.

Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.

Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.

Ariad Pharmaceuticals Up 75.1% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 02, 9:35AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 75.07% as of today's recent price of $6.43.

Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.

Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:59AM CDT
Karyopharm Therapeutics stock fell 5.2% last trading session, reversing its recent trend

Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.

IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.

Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Pacira's Exparel Positive in Phase IV Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:30AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced significant results from a series of phase IV studies on Exparel.

QLT Inc. (QLTI) in Focus: Stock Surges 14.63% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 7:44AM CDT
QLT Inc. (QLTI) was a big mover last session, as the company saw its shares rally nearly 15% on the day.

Clinical Studies, Trials Results, Appointments, and Technical Updates - Analyst Notes on Ohr, Ariad, Arrowhead, CytRx and Karyopharm Therapeutics
PR Newswire - Fri Jun 27, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Arrowhead Research Corp. (NASDAQ: ARWR), CytRx Corporation (NASDAQ: CYTR) and Karyopharm Therapeutics, Inc. (NASDAQ: KPTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4203-100free.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kenneth Spells: Championing Education Leadership in 2026

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

Winter Prep: Home Safety Vital for Older Adults

Cold Weather is All About Precaution It ain't the first day at the fair when you realize winter's sneaking up, and with it, the looming concern of older family members hunkering down indoors. Executive Home Care's calling out, saying it straight: if you've got seniors in your midst, now's the time to batten down the hatches. The winter months can turn into a slippery...

ITG Names Juliette Aiken CMO to Boost Storyteq's Reach

How do you put the throttle down on AI-driven content in a market that’s gasping for more? You bring in a heavyweight. Storyteq, the brainchild platform of Inspired Thinking Group (ITG), has roped in Juliette Aiken as their new Chief Marketing Officer. A veteran of the field, Juliette is tasked with propelling Storyteq from strong performer to an unbeatable force. New...

SEC Enforcement Lags: FY26 Sees Subdued Activity Surge

Parsing the Numbers: SEC's FY26 Performance It's like watching paint dry in the middle of a trading frenzy; the SEC's enforcement actions in FY26 were nothing to write home about. A mere 308 enforcement actions graced the ledger, a stunning 57% dive below the average from FY18 through FY25. When you think about the established numbers, it feels like the SEC decided to...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

AppLovin Faces Lawsuit Over AI Claims: Investor Alert

AI Promises or Pipedreams? AppLovin Corporation finds itself in a bit of hot water, and if you've got skin in this game, you've probably felt the heat. So, what's stirring the pot? A class action lawsuit against AppLovin (NASDAQ: APP) for allegedly pulling the wool over investors' eyes with overstated claims about their generative AI tool. Class Action: Weighing the...

York Space Systems Faces Securities Law Class Action

Unexpected Turbulence at York Space Systems Just when you thought things might be smooth sailing, York Space Systems (NYSE: YSS) finds itself on the hot seat. This fledgling aerospace player is now wrangling with a class action lawsuit for allegedly breaking federal securities laws. Call it a wake-up call from DJS Law Group encouraging investors who've had their fingers...

S?LACE Boats Unveils First Catamaran, the 41CT

Setting a New Course with the 41CT Picture this: a company known for pushing the envelope does it again, but this time, they aren't just elbowing their way into the catamaran market—they're redefining it. S?LACE Boats has unveiled their all-new 41CT center console catamaran. Not just another addition, it's practically a game-changer for anyone passionate about offshore...

Millrose Investors Face Unveiling of Financial Missteps

A Cold Shower for Millrose Properties' Investors Investing in Millrose Properties, Inc. (NYSE: MRP) didn't quite pan out as some folks hoped. On the heels of Hunterbrook's report about dubious deals, the Company's stock tumbled 8.53%, smacking investors with a not-so-gentle reminder of market realities. Sure, stocks can dip and dive like a rollercoaster, but when it...

Goodyear Preps for Q3 2026 Earnings Report, Call

Gearing Up for Goodyear's Latest Financials Here we go, folks—Goodyear Tire & Rubber Company is ready to roll out their third quarter's financial results for 2026. Come November 4, after the market goes to sleep, the big wigs at Goodyear will toss out the numbers. We’ll all get the chance to dig into the figures that they’ll slap on their investor website. Then,...